Neupogen (filgrastim) Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Neupogen (filgrastim) is a recombinant granulocyte colony-stimulating factor (G-CSF) that promotes the production of white blood cells in the bone marrow. It is used to prevent infections in patients with neutropenia caused by chemotherapy, bone marrow transplantation, or certain medical conditions.

The main forms of Neupogen (filgrastim) are biologic and biosimilar. Biologic drugs are produced from living organisms and involve complex manufacturing processes to achieve specific therapeutic effects. Its indications include chemotherapy-induced neutropenia, chronic neutropenia, and other related conditions. Neupogen is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have influenced the neupogen market by increasing costs for imported biologic raw materials, formulation inputs, and cold-chain transport systems. These pressures have affected hospital and retail pharmacy pricing, especially in regions reliant on imported biologics. Asia-pacific and latin america are among the most affected regions due to limited domestic production capacity. However, tariffs have supported local biosimilar manufacturing, encouraged supplier diversification, and strengthened long-term supply continuity.

The neupogen (filgrastim) market research report is one of a series of new reports from The Business Research Company that provides neupogen (filgrastim) market statistics, including neupogen (filgrastim) industry global market size, regional shares, competitors with a neupogen (filgrastim) market share, detailed neupogen (filgrastim) market segments, market trends and opportunities, and any further data you may need to thrive in the neupogen (filgrastim) industry. This neupogen (filgrastim) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neupogen (filgrastim) market size has grown strongly in recent years. It will grow from $1.4 million in 2025 to $1.48 million in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to growth in chemotherapy utilization, high infection risk in neutropenic patients, clinical validation of g-csf therapy, hospital-centered cancer care, limited early treatment options.

The neupogen (filgrastim) market size is expected to see strong growth in the next few years. It will grow to $1.81 million in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing cancer incidence, expansion of biosimilar adoption, growth in outpatient oncology services, improved access to biologic therapies, focus on infection prevention. Major trends in the forecast period include rising use of supportive care in oncology, expansion of chemotherapy-induced neutropenia management, increased adoption of biologic growth factors, shift toward outpatient neutropenia treatment, growing use of biosimilar alternatives.

The increasing prevalence of various diseases is expected to drive the growth of the Neupogen (filgrastim) market in the coming years. Diseases are disruptions in the structure or function of the body that produce specific symptoms or affect certain areas, often caused by infections, genetics, environmental factors, or lifestyle choices. The rising occurrence of these conditions is fueled by factors such as aging populations, sedentary lifestyles, higher pollution levels, poor dietary habits, and the global spread of infectious pathogens. Neupogen (filgrastim) helps manage complications from chemotherapy-induced neutropenia by stimulating neutrophil production, thereby enhancing the immune system's ability to fight infections in immunocompromised patients. It plays a key role in reducing hospitalizations, managing infection risks, and supporting uninterrupted cancer treatment regimens for patients undergoing intensive therapies. For example, in April 2024, Allergy UK, a UK-based national charity, reported that over 21 million people in the UK were affected by allergies, making it the most commonly reported chronic condition in 2022, with projections suggesting that by 2026, half of Europe's population will experience at least one allergy. Additionally, in June 2022, Macmillan Cancer Support, a UK-based cancer charity, reported that 3 million people were living with cancer in the UK in 2022, with projections reaching nearly 3.5 million by 2025 and 4 million by 2030. Therefore, the rising prevalence of various diseases is driving the Neupogen (filgrastim) market.

Government initiatives in healthcare research and development are also expected to support the growth of the Neupogen (filgrastim) market. Such initiatives refer to targeted actions, programs, policies, or projects undertaken by governmental bodies at local, regional, national, or international levels to address specific healthcare needs and drive positive outcomes. Several governments are implementing programs to support aspects of Neupogen (filgrastim) development and use. For example, in May 2023, the UK Department of Health and Social Care announced a $749.09 million (£650 million) "Life Sci for Growth" package to boost the life sciences sector. This package included $139.44 million (£121 million) to accelerate commercial clinical trials, $177.47 million (£154 million) to expand the UK Biobank's capabilities, and incentives of up to $288.11 million (£250 million) to attract pension-fund investment into the sector. Therefore, government initiatives for research and development in healthcare are driving the Neupogen (filgrastim) market.

Leading companies in the Neupogen (filgrastim) market are increasingly developing innovative filgrastim biosimilars to offer cost-effective and accessible alternatives for treating chemotherapy-induced neutropenia. Filgrastim biosimilars are biologic medicines that closely replicate the original Neupogen in terms of safety, efficacy, and structure, primarily used to stimulate neutrophil production in chemotherapy patients to prevent neutropenia. For instance, in September 2024, Tanvex BioPharma, a US-based biopharmaceutical company, received FDA approval for Nypozi (filgrastim-txid), a biosimilar referencing Amgen's Neupogen. Nypozi was one of three biosimilars approved by the FDA on the same day, contributing to a total of 55 biosimilars cleared in the United States as of June 2024. It is indicated to reduce the incidence of infection, as evidenced by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs.

Major companies operating in the neupogen (filgrastim) market are Amgen Inc.

North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neupogen (filgrastim) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The neupogen (filgrastim) market consists of sales of formulations, pre-filled syringes, vials for injection, and long-acting pegylated G-CSF derivatives. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neupogen (filgrastim) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses neupogen (filgrastim) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neupogen (filgrastim) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neupogen (filgrastim) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Biologic; Biosimilar
• 2) By Indication: Chemotherapy Induced Neutropenia; Chronic Neutropenia; Others
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Amgen Inc.
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.